DVL2 and central nervous system cancer: Combined collective public datasets from eight studies that are examining low‐grade gliomas and glioblastomas encompassing 4216 samples demonstrate the following distribution: somatic mutations were found in 8/4216 (0.19%) cases for DVL1, 12/4216 (0.28%) for DVL2 and 5/4216 (0.12%) for DVL3.